| Jula Inrig |
Jula Inrig is Chief Medical Officer at Travere Therapeutics, Inc.
She received a doctorate from Loma Linda University and an undergraduate degree from California State University-Sacramento. |
| Sandra Calvin |
Sandra Calvin occupies the position of Chief Accounting Officer, VP & Controller for Travere Therapeutics, Inc.
Ms. Calvin received an undergraduate degree from San Diego State University. |
| Peter Heerma |
Peter Heerma is Chief Commercial Officer for Retrophin, Inc.
He previously was GM-Oncology & Cardiovascular Products at Amgen, Inc., Senior Director-Portfolio Strategy at AbbVie, Inc. and Director-Commercial Strategy Renal Care at Abbott Laboratories.
Mr. Heerma received a graduate degree from the University of Lund and an undergraduate degree from Stenden University. |
| Noah L. Rosenberg |
Presently, Noah L. Rosenberg holds the position of Chief Medical Officer at Travere Therapeutics, Inc.
In his past career he was Chief Medical Officer at Esperion Therapeutics, Inc., Chief Medical Officer of Medimetriks Pharmaceuticals, Inc. and Executive Director & Head-Cardiovascular at Forest Research Institute, Inc.
He received an undergraduate degree from The Johns Hopkins University and a doctorate from Drexel University College of Medicine. |
| Laura M. Clague |
Currently, Laura M. Clague holds the position of Chief Financial Officer at Travere Therapeutics, Inc. She is also on the board of Genasys, Inc. and Fluidigm Corp.
In the past she held the position of Supervisor-Internal Audit at Cubic Corp., CFO-San Diego & Ohio Operations at Amylin Pharmaceuticals, Inc. and Director-Finance & Accounting Operations at Sony Electronics, Inc.
Ms. Clague received an undergraduate degree from Menlo College. |
| Gary A. Lyons |
Founder of GL Biomed, Gary A. Lyons is a businessperson who has been at the helm of 5 different companies and currently holds the position of Chairman at Rigel Pharmaceuticals, Inc., Chairman for Travere Therapeutics, Inc., President at GL Biomed and advisors at Healthcare Royalty Management LLC. Gary A. Lyons is also on the board of Neurocrine Biosciences, Inc. (former President, Chief Executive Officer & Director), Eledon Pharmaceuticals, Inc. and Brickell Biotech, Inc.
In the past Mr. Lyons occupied the position of Executive Chairman at NeurogesX, Inc., Vice President-Business Development & Sales at Genentech, Inc. and Sales Director-American Critical Care at American Hospital Supply Corp.
Gary A. Lyons received an undergraduate degree from the University of New Hampshire and an MBA from Kellogg School of Management. |
| Stephen J. Aselage |
Stephen J. Aselage is a businessperson who has been at the helm of 6 different companies and presently occupies the position of Chairman for Acer Therapeutics, Inc. and Chief Executive Officer for Kyalin Biosciences, Inc. Mr. Aselage is also on the board of BioCryst Pharmaceuticals, Inc., Patara Pharma LLC and Travere Therapeutics, Inc. (former President, Chief Executive Officer & Director).
In his past career he occupied the position of Executive VP-Global Commercial Operations at CTI BioPharma Corp., Chief Business Officer & Executive Vice President at BioMarin Pharmaceutical, Inc., Director-Sales & Marketing at Advanced Tissue Sciences, Inc., Chairman for Acer Therapeutics, Inc., Chairman at Desert Gateway, Inc., Chief Executive Officer & Director at Retrophin LLC, Sales Manager at Genentech, Inc., Senior VP-North American Sales & Marketing at SangStat Medical Corp., Senior VP-North American Sales & Marketing at Genzyme Corp. and Sales Manager at Rorer Pharmaceuticals, Inc.
Stephen J. Aselage received an undergraduate degree from the University of Notre Dame. |
| Eric M. Dube |
Presently, Eric M. Dube is President, Chief Executive Officer & Director at Travere Therapeutics, Inc. He is also on the board of Biotechnology Innovation Organization, BIOCOM, Reneo Pharmaceuticals, Inc. and Aids United.
In the past Dr. Dube held the position of SVP & Head-Global Respiratory Franchise at GlaxoSmithKline Plc President & Head-North America at ViiV Healthcare Ltd. and Senior Vice President & Head-Respiratory at GlaxoSmithKline KK (both are subsidiaries of GlaxoSmithKline Plc).
He received an undergraduate degree from Santa Clara University and a graduate degree and a doctorate from Cornell University. |
| Roy D. Baynes |
Roy D. Baynes is on the board of Natera, Inc., Travere Therapeutics, Inc. and Atara Biotherapeutics, Inc. and Member of American Society of Clinical Oncology, Member of American Association for Cancer Research, Member of American Society of Hematology and SVP & Head-Global Clinical Development at Merck Research Laboratories Massachusetts LLC.
Dr. Baynes previously was Chief Medical Officer for Merck & Co., Inc., VP-Global Development & Head-Hematology Oncology at Amgen, Inc., SVP-Oncology, Inflammation & Respiratory at Gilead Sciences, Inc. and Professor at Barbara Ann Karmanos Cancer Institute.
He received a doctorate and a graduate degree from the University of the Witwatersrand. |
| Timothy P. Coughlin |
Timothy P. Coughlin is on the board of aTyr Pharma, Inc., Fate Therapeutics, Inc. and Travere Therapeutics, Inc. In his past career he occupied the position of Chief Financial Officer at Neurocrine Biosciences, Inc., Vice President-Financial Services at Catholic Health Initiatives, Senior Manager-Health Sciences Practice at Ernst & Young LLP and Vice President-Financial Services at CommonSpirit Health (Illinois).
He received an undergraduate degree from Temple University (Pennsylvania) and a graduate degree from San Diego State University. |
| Jeffrey A. Meckler |
Jeffrey A. Meckler is a businessperson who has been at the head of 9 different companies and presently is Chief Executive Officer & Director at Indaptus Therapeutics, Inc. Mr. Meckler is also on the board of Children of Bellevue, Inc. (former President) and Travere Therapeutics, Inc. (former Chairman).
He previously held the position of Chief Executive Officer & Director at Cocrystal Pharma, Inc., Chief Executive Officer of Trieber Therapeutics, Inc., Managing Director at Andra Group, Inc., Independent Director at QLT, Inc., Chief Executive Officer & Director at Cypress Bioscience, Inc., Vice Chairman & Chief Executive Officer of Intec Pharma Ltd. and President, CEO, Secretary & Director at Intec Parent, Inc. (United States).
Jeffrey A. Meckler received an undergraduate degree and a graduate degree from Tepper School of Business and a graduate degree from Fordham University School of Law. |
| Suzanne Louise Bruhn |
Suzanne Louise Bruhn occupies the position of Chief Executive Officer, President & Director at Tiaki Therapeutics, Inc. Dr. Bruhn is also on the board of EMPath, Travere Therapeutics, Inc. and Pliant Therapeutics, Inc.
She previously occupied the position of President, Chief Executive Officer & Director at Proclara Biosciences, Inc., President & Chief Executive Officer at Promedior, Inc., SVP-Strategic Planning & Program Management at Shire Plc and Senior VP-Strategic Planning & Program Management at Shire Human Genetic Therapies, Inc.
She received a doctorate from Massachusetts Institute of Technology and an undergraduate degree from Iowa State University. |
| Sandra E. Poole |
Currently, Sandra E. Poole holds the position of Chief Operating Officer for Mythic Therapeutics, Inc. Ms. Poole is also on the board of ViaCyte, Inc. and Travere Therapeutics, Inc.
In her past career she was Chief Operating Officer at Advantagene, Inc., Chief Operating Officer for LogicBio Therapeutics, Inc., EVP-Technical Operations & Commercial Development at ImmunoGen, Inc., Managing Director at S. Poole Consulting LLC and Senior Vice President-Biologics Manufacturing at Genzyme Corp.
Sandra E. Poole received a graduate degree and an undergraduate degree from The University of Waterloo. |
| Ron Squarer |
Currently, Ron Squarer holds the position of Chairman of ADC Therapeutics SA. Mr. Squarer is also on the board of Deciphera Pharmaceuticals LLC, Travere Therapeutics, Inc. and Deciphera Pharmaceuticals, Inc.
Mr. Squarer previously held the position of Chief Executive Officer & Director at Array BioPharma, Inc., Principal at Smithkline Beecham Plc, Chief Commercial Officer & Senior Vice President at Hospira, Inc. and Senior Vice President-Business Development of Mayne Pharma Ltd.
He received an undergraduate degree from the University of California, Berkeley and an MBA from Kellogg School of Management. |
| John A. Orwin |
John A. Orwin occupies the position of President, Chief Executive Officer & Director at Atreca, Inc. He is also on the board of Seagen Inc., Biotechnology Innovation Organization and Travere Therapeutics, Inc.
Mr. Orwin previously was Chairman of Affymax, Inc., Franchise Vice President-Oncology at Johnson & Johnson Vice President-Oncology Franchise at Janssen Biotech, Inc. and Marketing Director-Oncology Division at ALZA Corp. (both are subsidiaries of Johnson & Johnson), Independent Director at NeurogesX, Inc., Chief Executive Officer of Relypsa, Inc., Senior Vice President-BioOncology Business Unit at Genentech, Inc., Product Manager-Oncology Division at Schering-Plough Corp., Vice President-Marketing of SangStat Medical Corp. and Marketing Director for Rhone-Poulenc Rorer Pharmaceuticals, Inc.
Mr. Orwin received an undergraduate degree from Rutgers State University of New Jersey and an MBA from The Leonard N Stern School of Business. |
